Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 92

1.

New treatments for incontinence. Find out which of the latest therapies are worth trying.

[No authors listed]

Harv Womens Health Watch. 2014 Mar;21(7):7. No abstract available.

PMID:
24941474
2.

Pharmacologic management of bladder dysfunction in adult women.

O'Dell K.

J Obstet Gynecol Neonatal Nurs. 2014 Mar-Apr;43(2):253-63. doi: 10.1111/1552-6909.12287. Epub 2014 Feb 6. Review.

PMID:
24502427
3.

Re: The efficacy and tolerability of the β3-adrenoceptor agonist mirabegron for the treatment of symptoms of overactive bladder in older patients.

Griebling TL.

J Urol. 2015 Mar;193(3):947. doi: 10.1016/j.juro.2014.12.072. Epub 2014 Dec 18. No abstract available.

PMID:
25765412
4.

Drugs for urologic disorders.

Bridgeman MB, Dalal KS.

Nursing. 2015 Jun;45(6):68. doi: 10.1097/01.NURSE.0000465676.91031.2b. No abstract available.

PMID:
25969889
5.

[Urinary incontinence: what's new in therapy?].

Becher KF, Sieber CC.

Dtsch Med Wochenschr. 2015 Feb;140(3):164-7. doi: 10.1055/s-0041-100150. Epub 2015 Feb 6. Review. German. No abstract available.

PMID:
25658400
6.

In brief: Oxytrol OTC.

[No authors listed]

Med Lett Drugs Ther. 2013 Sep 16;55(1425):76. No abstract available.

PMID:
24662958
7.

Discovery history and clinical development of mirabegron for the treatment of overactive bladder and urinary incontinence.

Sacco E, Bientinesi R, Tienforti D, Racioppi M, Gulino G, D'Agostino D, Vittori M, Bassi P.

Expert Opin Drug Discov. 2014 Apr;9(4):433-48. doi: 10.1517/17460441.2014.892923. Epub 2014 Feb 22. Review.

PMID:
24559030
8.

Combination of solifenacin and mirabegron for overactive bladder management.

Cornu JN.

BJU Int. 2015 Oct;116(4):498-9. doi: 10.1111/bju.13142. No abstract available.

9.

Stress urinary incontinence and overactive bladder syndrome: current options and new targets for management.

Elser DM.

Postgrad Med. 2012 May;124(3):42-9. doi: 10.3810/pgm.2012.05.2547. Review.

PMID:
22691898
10.

Cochrane Review Summary: Pelvic floor muscle training added to another active treatment versus the same active treatment alone for urinary incontinence in women.

Trivedi D.

Prim Health Care Res Dev. 2015 Nov;16(6):545-7. doi: 10.1017/S1463423615000419. Epub 2015 Aug 5. Review. No abstract available.

PMID:
26244696
11.

The pharmacologic management of idiopathic overactive bladder in primary care.

Ellsworth PI.

J Fam Pract. 2014 Feb;63(2 Suppl):S38-45. Review. No abstract available.

PMID:
24527484
12.

A proof-of-concept study: mirabegron, a new therapy for overactive bladder.

Chapple CR, Amarenco G, López Aramburu MA, Everaert K, Liehne J, Lucas M, Vik V, Ridder A, Snijder R, Yamaguchi O; BLOSSOM Investigator Group.

Neurourol Urodyn. 2013 Nov;32(8):1116-22. doi: 10.1002/nau.22373. Epub 2013 Feb 19.

PMID:
23424164
13.

[Epistaxis as a side effect of treatment of bladder hyperactivity with oxybutynin].

Molina A, Pérez A, Pisón J.

An Sist Sanit Navar. 2013 Jan-Apr;36(1):135-6. Spanish. No abstract available.

14.

Transdermal oxybutynin. A viewpoint by Michael Chancellor.

Chancellor M.

Drugs Aging. 2003;20(11):865-6. No abstract available.

PMID:
12964893
15.

Oxybutynin and urinary incontinence.

Castleden CM, Battcock TM, Duffin HM.

Age Ageing. 1990 Jan;19(1):72-3. No abstract available.

PMID:
2316427
16.

The use of oxybutynin in patients treated by means of botulinum neurotoxin A for neurogenic detrusor overactivity: an observational study.

Finazzi-Agrò E, Topazio L, Perugia C, Lombardi G, Finita Celso M, De Nunzio C, Del Popolo G.

Spinal Cord. 2013 Aug;51(8):637-41. doi: 10.1038/sc.2013.42. Epub 2013 May 21.

PMID:
23689390
17.
18.

Editorial comment on: Cizolirtine citrate, an effective treatment for symptomatic patients with urinary incontinence secondary to overactive bladder: a pilot dose-finding study.

Lazzeri M.

Eur Urol. 2009 Jul;56(1):191-2. doi: 10.1016/j.eururo.2008.04.029. Epub 2008 Apr 18. No abstract available.

PMID:
18485574
19.

Mirabegron for male lower urinary tract symptoms.

Suarez O, Osborn D, Kaufman M, Reynolds WS, Dmochowski R.

Curr Urol Rep. 2013 Dec;14(6):580-4. doi: 10.1007/s11934-013-0363-4.

PMID:
23913200
20.

Modern pharmacotherapy of urge urinary incontinence in the USA: tolterodine and oxybutynin.

Rovner ES, Wein AJ.

BJU Int. 2000 Oct;86 Suppl 2:44-53; discussion 53-4. No abstract available.

Supplemental Content

Support Center